2nd Quarter - Report — DIALYSIS PATIENT CITIZENS for DIALYSIS PATIENT CITIZENS (2012)

Firm

DIALYSIS PATIENT CITIZENS

Client

DIALYSIS PATIENT CITIZENS

Income

—

Expenses

$25,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Urge Congress to avoid sequestration and the disproportional cuts for treating kidney disease patients Facilitating patient choice and access to all modalities for VA dialysis patients

Lobbyist	Covered position, as disclosed
HRANT JAMGOCHIAN	—
CARRIE E LAMB	—

Contacted: SENATE; Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Centers For Disease Control & Prevention (CDC); Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Coverage of ESRD in Essential Health Benefits Application of tax credits and cost-sharing subisidies for ESRD patients in the exchange Ensuring adequacy of networks and consumer protections in exchanges S. 2163 / H.R. 6011 - Kidney Disease Equitable Acess, Prevention and Research Act

Lobbyist	Covered position, as disclosed
HRANT JAMGOCHIAN	—
CARRIE E LAMB	—

Contacted: Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); SENATE; White House Office; Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA)

Bills named: H.R. 6011 (112th), S. 2163 (112th)

Medicare/Medicaid MMM

S. 1454 / H.R. 2969 - Comprehensive immunosuppressive drug coverage for kidney transplant patients Potential incentives for innovation in ESRD bundled payment system Transition of oral-only medications into ESRD bundle S. 3271 - Equal access to Medicare options for kidney disease patient, by extending guaranteed issuance of Medigap policies

Lobbyist	Covered position, as disclosed
HRANT JAMGOCHIAN	—
CARRIE E LAMB	—

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); White House Office; Veterans Affairs, Dept of (VA); SENATE; Treasury, Dept of; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA)

Bills named: H.R. 2969 (112th), S. 1454 (112th), S. 3271 (112th)

Medical/Disease Research/Clinical Labs MED

Supporting innovative pilots to reduce and potentially prevent ESRD Importance of anemia management for ESRD patients Prioritizing patient role in infection prevention efforts at dialysis facilities Prioritize patient safety in developing procedure for approval of "generic" IV Iron

Lobbyist	Covered position, as disclosed
HRANT JAMGOCHIAN	—

Contacted: Veterans Affairs, Dept of (VA); White House Office; SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Treasury, Dept of

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.